Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: TokyoMex who wrote (15862)	5/8/1998 10:48:00 AM
From: Wayne Rumball	Respond to of 34592

FASC To: Lee Bush (144 ) From: GJC Thursday, May 7 1998 12:16PM ET Reply # of 153 This was posted on Yahoo last Apr 14th... I believe most of it still applies. From what I understand, the financials are complete and should be out soon. Also, the good news rumor is that the long term financing went through and FASC is now debt free. We'll see... Here is a message I received from the CFO: The company is still in existence. The company continues to advance in all three areas of its technology but continues to be hampered by insufficient working capital. Management is quite focused on obtaining sufficient working capital so that they can proceed move forward and restructure its affairs. The 10K for June 30, 1997 and the 10Q for Dec have been filed. The mine operation has just commenced production in Blythe and should produce at least 15,000 tons per month. The product will be sold to farms, wholesalers, cement companies, and as needed, to our Bakersfield plant. The Bakersfield plant is operating and has a contract to process potash for a client in Utah. There are numerous orders available in Bakersfield at the present time but we are hampered somewhat by the working capital shortage. Testing of the sludge has advanced to the point that a extensive test program is contemplated on the west coast of the USA in the next 2-3 months, for a period of at least 3 months. Should this program be successful, FASC will obtain EPA approval for the process, and the test facility would contract for a number of machines. Testing generally has shown that the moisture content reduces from 80% to less than 3% while the pathegons are essentially all removed. EPA approval more or less gives us an entry to any municipal facility in the USA with credibility. Progress is being made with a third party to finalize development of the rubber processing aspect of the technology. This 3rd party would spend the necessary R&D dollars to advance our process to a commercial entity. The company is attempting to finalize a placement of between $500,000 and $1,000,000U.S. in order to: retire existing debt to trade creditors from the startup; retire the debt on the technology; Working capital to operate the Bakersfield plant. Our business outlook is exceptional if we are successful in obtaining the necessary funding. We fully intend to develop as a three dimensional (divisons) company. These are industrial minerals, sludge, and rubber. The technology is also applicable to other applications such as glass, but we are not pursuing those at the present time. We agree with you that the technology is promising and we recognize that there have been no press releases lately, but management is working hard to solve the issues outstanding and is not intentionally ignoring the shareholders. Message 4349500 Message 4351277 Message 4363081 messages.yahoo.com.

To: TokyoMex who wrote (15862)	5/8/1998 10:53:00 AM
From: Steven Angelil	Read Replies (1) \| Respond to of 34592

Tokyo, I'm in right behind you (unfortunately at 40.25). What are the details we can expect and when? Thanks Steve

To: TokyoMex who wrote (15862)	5/8/1998 11:10:00 AM
From: Alex Sharp	Respond to of 34592

Joe what happened to ISDN? It keeps going down? And when are the earnings coming out on COBR?

To: TokyoMex who wrote (15862)	5/8/1998 11:11:00 AM
From: Zakattack	Read Replies (2) \| Respond to of 34592

BPRX - Interesting News article: biz.yahoo.com Thursday May 7, 1:56 pm Eastern Time Company Press Release Bradley Pharmaceuticals Anticipates Significant Sales Increases for Lubrin Vaginal Moisturizer as a Result of the Popularity of Viagra FAIRFIELD, N.J.--(BUSINESS WIRE)--May 7, 1998--BRADLEY PHARMACEUTICALS, INC. (NASDAQ NM: BPRX - news) foresees male Viagra(R) (Registered trademark of Pfizer, Inc. NYSE: PFE) patients increased sexual drive significantly affecting female usage of Lubrin(R) Vaginal Lubricant inserts. It is estimated in excess of 20 million post-menopausal women currently suffer from vaginal dryness. Many health-care experts share the view of Karin Martin, Sex Therapist at Hillside Hospital's Sexuality Center in Lake Success, New York, who spoke about male patients in their mid 40's through 60's taking Viagra(R) and ''their partners are happy they are able to have a more complete sexual relationship.'' Many other experts including Glenda Carle, author of ''Don't Bet on the Prince!'', state that a number of women who have gone through menopause may have to use additional vaginal lubricants. Bradley Pharmaceuticals' reports increased sales for Lubrin(R) since the introduction of Viagra(R) and expects sales to increase more with increased sexual activity among middle-aged Viagra(R) users and their partners. Lubrin(R) is a leading vaginal lubricant specifically designed to provide fast and prolonged lubrication for vaginal dryness. It has been recommended for years by Obstetricians and Gynecologists as a proven, safe and reliable form of personal lubrication which is odorless, colorless and non-staining. Lubrin(R) which simulates the body's natural lubrication, is designed to be the most convenient, non-messy vaginal lubricant available. Lubrin(R), available without a prescription, is distributed nationally and available in independent pharmacies as well as pharmacy chains such as: Walgreens, CVS and Eckerds. BRADLEY PHARMACEUTICALS, INC. manufactures and markets brandname products and over-the-counter pharmaceuticals and health-related products throughout the United States as well as in twenty-six international markets. This release may contain forward-looking statements which reflect management's current views of future events and operations. These forward-looking statements are based on assumptions and external factors, including assumptions relating to regulatory action, capital requirements and competing products. Any changes in such assumptions are external factors and could produce significantly different results.

To: TokyoMex who wrote (15862)	5/8/1998 11:25:00 AM
From: Brian Gross	Respond to of 34592

MEDX - Conference Monday - Phase 2 Cancer trials on humans from yahoo thread of enmd Top:Business and Finance:Stocks:Healthcare:Biotechnology & Drugs:ENMD (EntreMed, Inc.) <- Previous Next -> Message 1136 of 1152Reply MEDXSDMAN222 May 8 1998 3:19AM EDTNext 2 weeks should be interesting with this one:MDX210 moving further! PRODUCTS UNDER DEVELOPMENT Medarex has five therapeutic products currently in clinical development and several products in pre-clinical investigation. Cancer MDX-210, an anti-cancer Bispecific to treat HER-2 positive tumors, is currently in Phase II clinical studies for prostate, renal and colon cancer. Interim results of the renal and prostate cancer studies demonstrated anti-tumor activity, including measurable reductions in tumor size, pulmonary metastases and serum prostate specific antigen (PSA) levels. HER-2 is overexpressed on a significant number of tumors, including prostate, renal, colon, non-small cell lung, gastric and pancreatic cancers. MDX-210 is being developed in conjunction with Novartis, Inc. MDX-447, an anti-cancer Bispecific for tumors that express the EGF receptor, is a collaborative product with Merck KGaA. MDX-447 is currently in Phase I/II clinical trials. Interim results of the Phase I/II studies demonstrated immunological activity at all doses. EGF-R (the epidermal growth factor receptor) is highly expressed on a significant number of breast, head and neck, brain, non-small cell lung and bladder tumors. MDX-22 is used to purge leukemia cells from the bone marrow of acute myeloid leukemia (AML) patients who are undergoing a transplant of their own bone marrow. Phase II results indicate that MDX-22 can promote long term disease free survival in AML patients. Phase III trials are expected to begin during the first quarter of 1998. MDX-220, a new anti-cancer Bispecific for tumors that express TAG-72, is in the final stages of pre-clinical development. An Investigational New Drug application is expected to be filed with the FDA in 1998. TAG-72 is expressed on a variety of cancers, including lung, colon, prostate, ovarian, endometrial, pancreatic and gastric. ÿ ÿ ÿ ÿ Autoimmune Diseases MDX-33, a monoclonal antibody that binds to FcgR1 receptors, is being developed to treat autoimmune hematological disorders such as Idiopathic Thrombocytopenia Purpura (ITP) and autoimmune hemolytic anemia. In a Phase I study, MDX-33 was well tolerated at a dose that is capable of modulating an immune response implicated in autoimmune diseases. Phase II trials are expected to begin in the first quarter of 1998. MDX-33 is being developed through a corporate alliance with Centeon L.L.C. Secondary Cataract MDX-RA, an immunotoxin designed to prevent secondary cataracts, is Medarex's first product in Phase III clinical trials. Results from Phase I/II studies demonstrated that MDX-RA treatment can reduce the clouding of the eye lens following cataract surgery, that causes secondary cataracts. Completion of the Phase III study is expected in late 2000. Medarex has a partnership with Santen Pharmaceuticals Co., Ltd. for the development and distribution of MDX-RA in Japan. ÿENMD:ÿ Quote ÿ\|ÿ Profile ÿ\|ÿResearch This Is a Reply to: Msg 1135 by BINGOmmmm View Replies to this Message <- Previous Next -> Message 1136 of 1152Reply ÿÿ ------------------------------------------------------------------------ Go to: Startÿ\|ÿMost Recentÿ\|ÿMessage List \| Message Number:ÿ ÿ ÿ All Boards ÿ Only in this Board ÿ All ÿÿ Boards & Topics ÿ Authors ------------------------------------------------------------------------ Terms and Conditions Yahoo! is a trademark of Yahoo! Inc. Copyright c 1994-98 Yahoo! All Rights Reserved.